Severe Anemia Due to Parvovirus Infection Following Treatment with Rituximab in a Pediatric Kidney Transplant Recipient: Anemia after Treatment of Rituximab in Kidney Recipient Patient
Childhood Kidney Diseases
;
: 176-179, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-43529
ABSTRACT
Rituximab (RTX), a monoclonal antibody against the B-cell marker CD20, is commonly used as a treatment for antibody-mediated diseases or B-lymphocyte-mediated diseases. Destruction of B cells may reverse the disease course in many conditions; however, patients who are treated with RTX cannot respond appropriately to de novo infection due to lack of B lymphocytes. Here, we report one such case. A 7-year-old renal allograft recipient presented with severe anemia due to parvovirus infection after RTX treatment. The patient had focal segmental glomerulosclerosis and had received cadaveric kidney transplantation 6 months previously. She was treated with high-dose steroid for acute rejection and RTX for Epstein Barr Virus infection 3 months previously. At presentation, her hemoglobin level was 5.4 g/dL and leukocyte and platelet counts were normal. She had microcytic normochromic anemia and high viral load of parvovirus B19(70,578 copies/mL). Intravenous immunoglobulin (200 mg/kg.d) treatment controlled the progression of anemia and parvovirus infection. De novo parvovirus infection during the B lymphocyte-depletion period may have precipitated the severe anemia in this case. Close monitoring of infection is required after RTX therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Recuento de Plaquetas
/
Trasplante
/
Cadáver
/
Inmunoglobulinas
/
Linfocitos B
/
Glomeruloesclerosis Focal y Segmentaria
/
Trasplante de Riñón
/
Parvovirus
/
Herpesvirus Humano 4
/
Infecciones por Parvoviridae
Límite:
Niño
/
Humanos
Idioma:
Inglés
Revista:
Childhood Kidney Diseases
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS